Flume PA - Search Results

1

A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus.

Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, Johnson D, Flume PA. Szentpetery S, et al. Among authors: flume pa. J Cyst Fibros. 2022 Jul;21(4):721-724. doi: 10.1016/j.jcf.2022.04.005. Epub 2022 Apr 11. J Cyst Fibros. 2022. PMID: 35422395 Free article.

2

Transition programs in cystic fibrosis centers: perceptions of patients.

Anderson DL, Flume PA, Hardy KK, Gray S. Anderson DL, et al. Among authors: flume pa. Pediatr Pulmonol. 2002 May;33(5):327-31. doi: 10.1002/ppul.10083. Pediatr Pulmonol. 2002. PMID: 11948976

3

Transition programs in cystic fibrosis centers: perceptions of team members.

Flume PA, Taylor LA, Anderson DL, Gray S, Turner D. Flume PA, et al. Pediatr Pulmonol. 2004 Jan;37(1):4-7. doi: 10.1002/ppul.10391. Pediatr Pulmonol. 2004. PMID: 14679482

4

Impact of lung transplantation on site of death in cystic fibrosis.

Ford D, Flume PA. Ford D, et al. Among authors: flume pa. J Cyst Fibros. 2007 Nov 30;6(6):391-5. doi: 10.1016/j.jcf.2007.03.002. Epub 2007 Apr 20. J Cyst Fibros. 2007. PMID: 17448734 Free article.

5

Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis.

Flume PA, Ciolino J, Gray S, Lester MK. Flume PA, et al. J Cyst Fibros. 2009 Sep;8(5):321-5. doi: 10.1016/j.jcf.2009.07.004. Epub 2009 Aug 8. J Cyst Fibros. 2009. PMID: 19665944 Free article.

6

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE; VX 08-770-104 Study Group. Flume PA, et al. Chest. 2012 Sep;142(3):718-724. doi: 10.1378/chest.11-2672. Chest. 2012. PMID: 22383668 Free PMC article. Clinical Trial.

7

Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.

Stenbit AE, Bullington WM, Heh JL, Flume PA. Stenbit AE, et al. Among authors: flume pa. J Cyst Fibros. 2013 Jul;12(4):403-6. doi: 10.1016/j.jcf.2012.11.007. Epub 2012 Dec 20. J Cyst Fibros. 2013. PMID: 23266092 Free article.

8

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA. Stuart Elborn J, et al. Among authors: flume pa. J Cyst Fibros. 2015 Jul;14(4):507-14. doi: 10.1016/j.jcf.2014.12.013. Epub 2015 Jan 13. J Cyst Fibros. 2015. PMID: 25592656 Free article. Clinical Trial.

9

Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.

Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Gaggar A, et al. Among authors: flume pa. J Cyst Fibros. 2016 Mar;15(2):227-33. doi: 10.1016/j.jcf.2015.07.009. Epub 2015 Aug 28. J Cyst Fibros. 2016. PMID: 26321218 Free PMC article. Clinical Trial.

10

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS. Flume PA, et al. J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4. J Cyst Fibros. 2016. PMID: 26852040 Free article. Clinical Trial.

11

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR. Elborn JS, et al. Among authors: flume pa. J Cyst Fibros. 2016 Sep;15(5):634-40. doi: 10.1016/j.jcf.2016.01.005. Epub 2016 Feb 28. J Cyst Fibros. 2016. PMID: 26935334 Free article. Clinical Trial.

12

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW. Flume PA, et al. J Cyst Fibros. 2016 Nov;15(6):809-815. doi: 10.1016/j.jcf.2016.05.001. Epub 2016 May 24. J Cyst Fibros. 2016. PMID: 27233377 Free article. Clinical Trial.

13

Efficacy measures for clinical trials: A review series.

Flume PA, VanDevanter DR. Flume PA, et al. J Cyst Fibros. 2016 Jul;15(4):415. doi: 10.1016/j.jcf.2016.06.002. Epub 2016 Jun 15. J Cyst Fibros. 2016. PMID: 27316664 Free article. No abstract available.

14

Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy.

Elborn JS, Davies J, Mall MA, Flume PA, Plant B. Elborn JS, et al. Among authors: flume pa. J Cyst Fibros. 2017 Jan;16(1):163-164. doi: 10.1016/j.jcf.2016.11.009. Epub 2016 Dec 13. J Cyst Fibros. 2017. PMID: 27986495 Free article.

15

The challenges of maintaining momentum in CF drug development and approval - Commentary.

Flume PA, VanDevanter DR. Flume PA, et al. J Cyst Fibros. 2017 Mar;16(2):170-171. doi: 10.1016/j.jcf.2017.01.014. Epub 2017 Feb 5. J Cyst Fibros. 2017. PMID: 28179070 Free article. No abstract available.

16

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Donaldson SH, et al. Among authors: flume pa. J Cyst Fibros. 2017 May;16(3):371-379. doi: 10.1016/j.jcf.2017.01.009. Epub 2017 Feb 13. J Cyst Fibros. 2017. PMID: 28209466 Free article. Clinical Trial.

17

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators. West NE, et al. Among authors: flume pa. J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29. J Cyst Fibros. 2017. PMID: 28457954 Free PMC article.

18

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group. Sanders DB, et al. Among authors: flume pa. J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29. J Cyst Fibros. 2017. PMID: 28460885 Free PMC article.

19

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.

Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Flume PA, et al. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24. J Cyst Fibros. 2018. PMID: 28651844 Free article. Clinical Trial.

20

Learning's from the Editors Desk - 2017.

Bell SC, Castellani C, Flume PA. Bell SC, et al. Among authors: flume pa. J Cyst Fibros. 2017 Nov;16(6):645-646. doi: 10.1016/j.jcf.2017.10.001. J Cyst Fibros. 2017. PMID: 29150008 Free article. No abstract available.

21

ECFS best practice guidelines: the 2018 revision.

Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. Castellani C, et al. Among authors: flume pa. J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. J Cyst Fibros. 2018. PMID: 29506920 Free article. Review.

22

Optimizing outcomes of pulmonary exacerbations in cystic fibrosis.

Szentpetery S, Flume PA. Szentpetery S, et al. Among authors: flume pa. Curr Opin Pulm Med. 2018 Nov;24(6):606-611. doi: 10.1097/MCP.0000000000000519. Curr Opin Pulm Med. 2018. PMID: 30124523 Review.

23

Defining antimicrobial resistance in cystic fibrosis.

Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ; Antimicrobial Resistance in Cystic Fibrosis International Working Group. Kidd TJ, et al. Among authors: flume pa. J Cyst Fibros. 2018 Nov;17(6):696-704. doi: 10.1016/j.jcf.2018.08.014. Epub 2018 Sep 25. J Cyst Fibros. 2018. PMID: 30266518 Free article. Review.

24

Antimicrobial resistance in cystic fibrosis: Does it matter?

Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J; Antimicrobial Resistance in Cystic Fibrosis International Working Group. Flume PA, et al. J Cyst Fibros. 2018 Nov;17(6):687-689. doi: 10.1016/j.jcf.2018.08.015. Epub 2018 Sep 27. J Cyst Fibros. 2018. PMID: 30270113 Free article. No abstract available.

25

Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis.

Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL. Flume PA, et al. J Cyst Fibros. 2019 Sep;18(5):737-742. doi: 10.1016/j.jcf.2018.12.004. Epub 2018 Dec 23. J Cyst Fibros. 2019. PMID: 30587335 Free article. Clinical Trial.

26

JCF - progress in 2018.

Bell SC, Castellani C, Flume PA. Bell SC, et al. Among authors: flume pa. J Cyst Fibros. 2019 Jan;18(1):1-5. doi: 10.1016/j.jcf.2018.12.008. J Cyst Fibros. 2019. PMID: 30665544 Free article. No abstract available.

27

The study of CFTR modulators in the very young.

Flume PA. Flume PA. Lancet Respir Med. 2019 Apr;7(4):287-289. doi: 10.1016/S2213-2600(18)30503-4. Epub 2019 Jan 24. Lancet Respir Med. 2019. PMID: 30686766 No abstract available.

28

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR; Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group. Somayaji R, et al. Among authors: flume pa. J Cyst Fibros. 2019 Mar;18(2):236-243. doi: 10.1016/j.jcf.2019.01.008. Epub 2019 Jan 30. J Cyst Fibros. 2019. PMID: 30709744 Free article.

29

Predictors of pulmonary exacerbation treatment in cystic fibrosis.

Sanders DB, Ostrenga JS, Rosenfeld M, Fink AK, Schechter MS, Sawicki GS, Flume PA, Morgan WJ. Sanders DB, et al. Among authors: flume pa. J Cyst Fibros. 2020 May;19(3):407-414. doi: 10.1016/j.jcf.2019.06.008. Epub 2019 Jun 27. J Cyst Fibros. 2020. PMID: 31257102 Free PMC article.

30

Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices.

Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA; Antimicrobial Resistance International Working Group in Cystic Fibrosis. Zemanick E, et al. Among authors: flume pa. J Cyst Fibros. 2020 May;19(3):370-375. doi: 10.1016/j.jcf.2019.10.006. Epub 2019 Oct 31. J Cyst Fibros. 2020. PMID: 31680041 Free article.

31

Disruption in research publishing - the open access revolution.

Bell SC, Castellani C, Flume PA. Bell SC, et al. Among authors: flume pa. J Cyst Fibros. 2019 Nov;18(6):747-749. doi: 10.1016/j.jcf.2019.10.024. J Cyst Fibros. 2019. PMID: 31836188 Free article. No abstract available.

32

Finding the relevance of antimicrobial stewardship for cystic fibrosis.

Cogen JD, Kahl BC, Maples H, McColley SA, Roberts JA, Winthrop KL, Morris AM, Holmes A, Flume PA, VanDevanter DR, Waters V, Muhlebach MS, Elborn JS, Saiman L, Bell SC; Antimicrobial Resistance International Working Group in Cystic Fibrosis. Cogen JD, et al. Among authors: flume pa. J Cyst Fibros. 2020 Jul;19(4):511-520. doi: 10.1016/j.jcf.2020.02.012. Epub 2020 Feb 29. J Cyst Fibros. 2020. PMID: 32122785 Free article. Review.

33

Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers.

Low D, Wilson DA, Flume PA. Low D, et al. Among authors: flume pa. J Cyst Fibros. 2020 Jul;19(4):569-574. doi: 10.1016/j.jcf.2020.02.013. Epub 2020 Mar 13. J Cyst Fibros. 2020. PMID: 32178969 Free article.

34

Seven P's of publication practices.

Bell SC, Flume PA, Castellani C. Bell SC, et al. Among authors: flume pa. J Cyst Fibros. 2020 May;19(3):333-335. doi: 10.1016/j.jcf.2020.02.007. Epub 2020 Mar 31. J Cyst Fibros. 2020. PMID: 32245683 Free article. No abstract available.

35

Antimicrobial resistance: Concerns of healthcare providers and people with CF.

Bullington W, Hempstead S, Smyth AR, Drevinek P, Saiman L, Waters VJ, Bell SC, VanDevanter DR, Flume PA, Elborn S, Muhlebach MS; Antimicrobial Resistance International Working Group in Cystic Fibrosis. Bullington W, et al. Among authors: flume pa. J Cyst Fibros. 2021 May;20(3):407-412. doi: 10.1016/j.jcf.2020.05.009. Epub 2020 Jun 17. J Cyst Fibros. 2021. PMID: 32563724 Free article.

36

Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.

Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA. Harruff EE, et al. Among authors: flume pa. J Cyst Fibros. 2021 Mar;20(2):288-294. doi: 10.1016/j.jcf.2020.11.020. Epub 2020 Dec 16. J Cyst Fibros. 2021. PMID: 33341407 Free article.

37

JCF Year in Review.

Flume PA, Castellani C, Davies J. Flume PA, et al. J Cyst Fibros. 2021 Jan;20(1):1-2. doi: 10.1016/j.jcf.2021.01.004. J Cyst Fibros. 2021. PMID: 33526211 Free PMC article. No abstract available.

38

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080

39

Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.

Flume PA, Amelina E, Daines CL, Charlton B, Leadbetter J, Guasconi A, Aitken ML. Flume PA, et al. J Cyst Fibros. 2021 Nov;20(6):1003-1009. doi: 10.1016/j.jcf.2021.02.011. Epub 2021 Mar 11. J Cyst Fibros. 2021. PMID: 33715994 Free article. Clinical Trial.

40

Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.

Mingora CM, Flume PA. Mingora CM, et al. Among authors: flume pa. Chest. 2021 Oct;160(4):1232-1240. doi: 10.1016/j.chest.2021.06.017. Epub 2021 Jun 17. Chest. 2021. PMID: 34147501 Free PMC article. Review.

41

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.

Sawicki GS, Van Brunt K, Booth J, Bailey E, Millar SJ, Konstan MW, Flume PA. Sawicki GS, et al. Among authors: flume pa. J Cyst Fibros. 2022 Jan;21(1):96-103. doi: 10.1016/j.jcf.2021.07.003. Epub 2021 Jul 19. J Cyst Fibros. 2022. PMID: 34289939 Free PMC article.

42

Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition.

Hendrix SJ, Flume PA, First ER, Stone AA, Van Buskirk M. Hendrix SJ, et al. Among authors: flume pa. Nutr Clin Pract. 2022 Apr;37(2):344-350. doi: 10.1002/ncp.10831. Epub 2022 Feb 24. Nutr Clin Pract. 2022. PMID: 35199869 Free PMC article.

43

Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.

Mingora CM, Garcia BA, Mange KC, Yuen DW, Ciesielska M, van Ingen J, Flume PA, Dorman SE. Mingora CM, et al. Among authors: flume pa. BMC Infect Dis. 2022 Mar 12;22(1):246. doi: 10.1186/s12879-022-07250-4. BMC Infect Dis. 2022. PMID: 35279081 Free PMC article. Clinical Trial.

44

Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.

Gold LS, Hansen RN, Patrick DL, Tabah A, Heltshe SL, Flume PA, Goss CH, West NE, Sanders DB, VanDevanter DR, Kessler L. Gold LS, et al. Among authors: flume pa. J Cyst Fibros. 2022 Jul;21(4):594-599. doi: 10.1016/j.jcf.2022.03.001. Epub 2022 Mar 14. J Cyst Fibros. 2022. PMID: 35300932 Free PMC article. Clinical Trial.

45

From the Editor's Desk.

Flume PA. Flume PA. J Cyst Fibros. 2022 Mar;21(2):197-198. doi: 10.1016/j.jcf.2022.03.003. J Cyst Fibros. 2022. PMID: 35337599 Free PMC article. No abstract available.

46

Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry.

Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Szentpetery S, et al. Among authors: flume pa. J Cyst Fibros. 2022 Sep;21(5):777-783. doi: 10.1016/j.jcf.2022.03.010. Epub 2022 Apr 5. J Cyst Fibros. 2022. PMID: 35396178 Free PMC article.

47

Telehealth and CFTR modulators: Accelerating innovative models of cystic fibrosis care.

Prickett MH, Flume PA, Sabadosa KA, Tran QT, Marshall BC. Prickett MH, et al. Among authors: flume pa. J Cyst Fibros. 2023 Jan;22(1):9-16. doi: 10.1016/j.jcf.2022.07.002. Epub 2022 Jul 22. J Cyst Fibros. 2023. PMID: 35879227 Free article. Review.

48

Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States.

Collaco JM, Albon D, Ostrenga JS, Flume P, Schechter MS, Cromwell EA. Collaco JM, et al. J Cyst Fibros. 2023 May;22(3):456-463. doi: 10.1016/j.jcf.2022.12.004. Epub 2022 Dec 14. J Cyst Fibros. 2023. PMID: 36526554 Free article.

49

Combined Aerobic Exercise and Virtual Reality-Based Upper Extremity Rehabilitation Intervention for Chronic Stroke: Feasibility and Preliminary Effects on Physical Function and Quality of Life.

Ross RE, Hart E, Williams ER, Gregory CM, Flume PA, Mingora CM, Woodbury ML. Ross RE, et al. Among authors: flume pa. Arch Rehabil Res Clin Transl. 2022 Nov 11;5(1):100244. doi: 10.1016/j.arrct.2022.100244. eCollection 2023 Mar. Arch Rehabil Res Clin Transl. 2022. PMID: 36968163 Free PMC article.

50

Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis.

Peng G, Taylor-Cousar JL, Lee M, Keller A, West NE, Kazmerski TM, Goralski JL, Aitken ML, Roe AH, Hadjiliadis D, Uluer A, Flume PA, Mody S, Bray LA, Jain R. Peng G, et al. Among authors: flume pa. J Cyst Fibros. 2023 Sep;22(5):796-803. doi: 10.1016/j.jcf.2023.03.020. Epub 2023 Apr 5. J Cyst Fibros. 2023. PMID: 37029015 Free article.

51

Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.

McElvaney OJ, Heltshe SL, Odem-Davis K, West NE, Sanders DB, Fogarty B, VanDevanter DR, Flume PA, Goss CH; STOP2 Investigators. McElvaney OJ, et al. Among authors: flume pa. J Cyst Fibros. 2023 Sep;22(5):875-879. doi: 10.1016/j.jcf.2023.06.012. Epub 2023 Jul 6. J Cyst Fibros. 2023. PMID: 37407341 Free PMC article.

52

Experiences of cystic fibrosis newborn screening and genetic counseling.

Foil K, Christon L, Kerrigan C, Flume PA, Drinkwater J, Szentpetery S. Foil K, et al. Among authors: flume pa. J Community Genet. 2023 Dec;14(6):621-626. doi: 10.1007/s12687-023-00666-8. Epub 2023 Sep 1. J Community Genet. 2023. PMID: 37656403 Free PMC article.

53

Relationship between culture conversion and clinical outcomes in nontuberculous mycobacterial pulmonary disease: Narrative review.

Winthrop KL, Mingora CM, Varley CD, Dorman SE, Flume PA. Winthrop KL, et al. Among authors: flume pa. Respir Med. 2025 May;241:108052. doi: 10.1016/j.rmed.2025.108052. Epub 2025 Mar 23. Respir Med. 2025. PMID: 40132751 Free article. Review.

54

The Aging Patient with Cystic Fibrosis.

Sullivan LJ, Mingora CM, Flume PA. Sullivan LJ, et al. Among authors: flume pa. Drugs Aging. 2025 Jun;42(6):513-525. doi: 10.1007/s40266-025-01207-3. Epub 2025 Apr 24. Drugs Aging. 2025. PMID: 40274760 Free PMC article. Review.

55

PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report.

Szentpetery S, Riva D, Blumenfeld YJ, Engelhardt JF, Luna-Paredes C, Milla C, Schneider-Futschik EK, Sheffield JS, Darrah R, Davies JC, Flume PA, Foil KE, Fortner CN, Guimbellot JS, Lyerly AD, Mayer-Hamblett N, Ren CL, Spano J, Tillman EM, Trimble A, Wilfond BS, Taylor-Cousar JL. Szentpetery S, et al. Among authors: flume pa. J Cyst Fibros. 2025 Nov;24(6):1058-1066. doi: 10.1016/j.jcf.2025.07.015. Epub 2025 Aug 5. J Cyst Fibros. 2025. PMID: 40754574 Free article. Review.

56

A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria.

Daley CL, Flume PA, van Ingen J, Khare R, Mingora CM, Nguyen MH, Winthrop KL, Zha BS. Daley CL, et al. Among authors: flume pa. Eur Respir Rev. 2025 Nov 5;34(178):250038. doi: 10.1183/16000617.0038-2025. Print 2025 Oct. Eur Respir Rev. 2025. PMID: 41193247 Free PMC article.

57

Integration of psychological care into a nontuberculous mycobacteria (NTM) program in the Southeastern United States: A retrospective cohort study.

Christon LM, Bullington W, Sullivan L, Flume PA, Dorman S, Alkabab Y, Daigle B, Taylor B, Mingora C. Christon LM, et al. Among authors: flume pa. Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251394479. doi: 10.1177/17534666251394479. Epub 2025 Nov 12. Ther Adv Respir Dis. 2025. PMID: 41222255 Free PMC article.

58

Real-life use of bronchodilators and inhaled corticosteroids in cystic fibrosis and non-CF bronchiectasis, Do guidelines matter?

Garcia MAM, Flume PA. Garcia MAM, et al. Among authors: flume pa. J Cyst Fibros. 2026 Jan;25(1):9-12. doi: 10.1016/j.jcf.2025.12.013. Epub 2025 Dec 24. J Cyst Fibros. 2026. PMID: 41448972 Free article. No abstract available.

59

From the editor's desk.

Flume PA. Flume PA. J Cyst Fibros. 2026 Mar;25(2):189-194. doi: 10.1016/j.jcf.2026.03.007. Epub 2026 Mar 12. J Cyst Fibros. 2026. PMID: 41826130 No abstract available.

60

Cystic fibrosis care utilization from 2019-2023: a descriptive analysis of adult and pediatric CF care utilization in the post-ETI and post-pandemic Era.

Atteih SE, Mbassa RS, Collaco JM, Ostrenga JS, Todd J, Flume PA, Brown RF, Brown AW, Cromwell EA. Atteih SE, et al. Among authors: flume pa. J Cyst Fibros. 2026 Jun 2:S1569-1993(26)01641-3. doi: 10.1016/j.jcf.2026.05.018. Online ahead of print. J Cyst Fibros. 2026. PMID: 42230182

61

Pneumothorax in cystic fibrosis.

Flume PA. Flume PA. Chest. 2003 Jan;123(1):217-21. doi: 10.1378/chest.123.1.217. Chest. 2003. PMID: 12527625 Review.

62

An unusual presentation of cystic fibrosis in an adult.

Davé S, Honney S, Raymond J, Flume PA. Davé S, et al. Among authors: flume pa. Am J Kidney Dis. 2005 Mar;45(3):e41-4. doi: 10.1053/j.ajkd.2004.11.009. Am J Kidney Dis. 2005. PMID: 15754262 Review.

63

The delta F508 mutation in cystic fibrosis and impact on sinus development.

Woodworth BA, Ahn C, Flume PA, Schlosser RJ. Woodworth BA, et al. Among authors: flume pa. Am J Rhinol. 2007 Jan-Feb;21(1):122-7. doi: 10.2500/ajr.2007.21.2905. Am J Rhinol. 2007. PMID: 17283574

64

Making the diagnosis of cystic fibrosis.

Flume PA, Stenbit A. Flume PA, et al. Am J Med Sci. 2008 Jan;335(1):51-4. doi: 10.1097/MAJ.0b013e31815d2622. Am J Med Sci. 2008. PMID: 18195584 Review.

65

Pneumothorax in cystic fibrosis.

Flume PA. Flume PA. Curr Opin Pulm Med. 2011 Jul;17(4):220-5. doi: 10.1097/MCP.0b013e328345e1f8. Curr Opin Pulm Med. 2011. PMID: 21460730

66

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Wainwright CE, et al. Among authors: flume pa. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981758 Free PMC article. Clinical Trial.

67

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group. Moss RB, et al. Among authors: flume pa. Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9. Lancet Respir Med. 2015. PMID: 26070913 Free PMC article. Clinical Trial.

68

The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans?

Flume PA, VanDevanter DR. Flume PA, et al. Ann Intern Med. 2017 Apr 18;166(8):599-600. doi: 10.7326/M17-0564. Epub 2017 Mar 14. Ann Intern Med. 2017. PMID: 28289748 No abstract available.

69

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.

Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT; VX11-661-101 Study Group. Donaldson SH, et al. Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC. Am J Respir Crit Care Med. 2018. PMID: 28930490 Free PMC article. Clinical Trial.

70

Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis.

Brown KL, Flume PA. Brown KL, et al. Among authors: flume pa. J Genet Couns. 2018 Sep;27(5):1049-1054. doi: 10.1007/s10897-018-0220-1. Epub 2018 Feb 10. J Genet Couns. 2018. PMID: 29429040

71

Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies.

Jennings MT, Flume PA. Jennings MT, et al. Among authors: flume pa. Ann Am Thorac Soc. 2018 Aug;15(8):897-902. doi: 10.1513/AnnalsATS.201802-075FR. Ann Am Thorac Soc. 2018. PMID: 29812963 Free PMC article. Review.

72

Clinical care for cystic fibrosis: preparing for the future now.

Konstan MW, Flume PA. Konstan MW, et al. Among authors: flume pa. Lancet Respir Med. 2020 Jan;8(1):10-12. doi: 10.1016/S2213-2600(19)30334-0. Epub 2019 Sep 27. Lancet Respir Med. 2020. PMID: 31570320 No abstract available.

73

Cystic Fibrosis: Advances in Understanding and Treatment.

Flume PA, Goss CH, VanDevanter D. Flume PA, et al. Semin Respir Crit Care Med. 2019 Dec;40(6):699-700. doi: 10.1055/s-0039-3400453. Epub 2019 Dec 30. Semin Respir Crit Care Med. 2019. PMID: 31887767 No abstract available.

74

Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes.

Flume PA, VanDevanter DR. Flume PA, et al. Eur Respir J. 2020 Apr 3;55(4):2000105. doi: 10.1183/13993003.00105-2020. Print 2020 Apr. Eur Respir J. 2020. PMID: 32245773 Free article. No abstract available.

75

The Impact of COVID-19 in Cystic Fibrosis.

Flume PA, Saiman L, Marshall B. Flume PA, et al. Arch Bronconeumol. 2022 Jun;58(6):466-468. doi: 10.1016/j.arbres.2021.12.003. Epub 2021 Dec 17. Arch Bronconeumol. 2022. PMID: 34934258 Free PMC article. No abstract available.

76

Abdominal Surgical Procedures in Adult Patients With Cystic Fibrosis: What Are the Risks?

Hite MA, Gaertner WB, Garcia B, Flume PA, Maxwell PJ 4th, George VV, Curran T. Hite MA, et al. Among authors: flume pa. Dis Colon Rectum. 2022 Aug 1;65(8):e805-e815. doi: 10.1097/DCR.0000000000002162. Epub 2022 Jul 5. Dis Colon Rectum. 2022. PMID: 35030557 Free PMC article.

77

Role of hyperglycemia in cystic fibrosis pulmonary exacerbations.

Merjaneh L, Sidhaye AR, Vu PT, Heltshe SL, Goss CH, Flume PA, Kelly A, Rosenfeld M on behalf of the STOP2 investigators. Merjaneh L, et al. Among authors: flume pa. J Cyst Fibros. 2023 Sep;22(5):868-874. doi: 10.1016/j.jcf.2023.06.011. Epub 2023 Jun 30. J Cyst Fibros. 2023. PMID: 37394317 Free PMC article.

78

Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location.

Gold LS, Hansen RN, Heltshe SL, Flume PA, Goss CH, West NE, Sanders DB, Kessler L. Gold LS, et al. Among authors: flume pa. J Cyst Fibros. 2024 Mar;23(2):278-281. doi: 10.1016/j.jcf.2023.10.004. Epub 2023 Oct 5. J Cyst Fibros. 2024. PMID: 37805355 Free PMC article. Clinical Trial.

79

The impact of switching to race-neutral reference equations on FEV₁ percent predicted among people with cystic fibrosis.

Rosenfeld M, Cromwell EA, Schechter MS, Ren C, Flume PA, Szczesniak RD, Morgan WJ, Jain R. Rosenfeld M, et al. Among authors: flume pa. J Cyst Fibros. 2024 May;23(3):443-449. doi: 10.1016/j.jcf.2024.03.013. Epub 2024 Mar 30. J Cyst Fibros. 2024. PMID: 38556415 Free article.

80

Adapting the cystic fibrosis care model: Perspectives from people with CF, caregivers, and members of CF care teams.

Tran QT, Aliaj E, Olmsted MG, Hempstead SE, Lomas PH, Brown RF, Flume PA, Brown AW. Tran QT, et al. Among authors: flume pa. J Cyst Fibros. 2024 Nov;23(6):1066-1071. doi: 10.1016/j.jcf.2024.09.002. Epub 2024 Sep 25. J Cyst Fibros. 2024. PMID: 39327190

81

Cystic fibrosis foundation position paper: Redefining the CF care model.

Goetz DM, Brown RF, Filigno SS, Bichl SL, Nelson AL, Merlo CA, Juel R, Lomas P, Hempstead SE, Tran Q, Brown AW, Flume PA; CFF Care Model Committee. Goetz DM, et al. Among authors: flume pa. J Cyst Fibros. 2024 Nov;23(6):1055-1065. doi: 10.1016/j.jcf.2024.08.007. Epub 2024 Sep 25. J Cyst Fibros. 2024. PMID: 39327191 Free article. Review.

82

Cystic fibrosis foundation position paper: Redefining the cystic fibrosis care team.

Brown RF, Close CT, Mailes MG, Gonzalez LJ, Goetz DM, Filigno SS, Preslar R, Tran QT, Hempstead SE, Lomas P, Brown AW, Flume PA; CFF Care Model Committee. Brown RF, et al. Among authors: flume pa. J Cyst Fibros. 2024 Nov;23(6):1045-1054. doi: 10.1016/j.jcf.2024.09.011. Epub 2024 Sep 25. J Cyst Fibros. 2024. PMID: 39327194 Free article. Review.

83

Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.

West NE, Konstan MW, Flume PA, VanDevanter DR, Magaret A, Mazurek H, Amelina EL, Laki I, Chiron R, Sutharsan S, Columbo C, Dorkin HL, Downey DG, Sole A, Hjelte L, Tullis E, Dgetluck N, Dinh Q, Constantine S, White B, Elborn JS, Chmiel JF; JBT101-CF-002 Study Group. West NE, et al. Among authors: flume pa. J Cyst Fibros. 2025 Jul;24(4):691-697. doi: 10.1016/j.jcf.2025.03.015. Epub 2025 May 26. J Cyst Fibros. 2025. PMID: 40425421 Clinical Trial.

84

Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.

McElvaney OJ, Heltshe SL, Sanders DB, West NE, Fogarty B, VanDevanter DR, Flume PA, Goss CH; STOP2 Investigators. McElvaney OJ, et al. Among authors: flume pa. J Cyst Fibros. 2026 Mar;25(2):210-217. doi: 10.1016/j.jcf.2025.12.007. Epub 2025 Dec 12. J Cyst Fibros. 2026. PMID: 41387145 Free PMC article. Clinical Trial.

85

Evaluating the association of antibiotic spectrum and treatment responses of cystic fibrosis pulmonary exacerbations.

Somayaji R, Cogen JD, VanDevanter D, LiPuma JJ, West NE, Sanders DB, Gerber JS, Kronman MP, Goss CH, Flume PA, Heltshe SL. Somayaji R, et al. Among authors: flume pa. J Cyst Fibros. 2026 Mar;25(2):218-224. doi: 10.1016/j.jcf.2025.12.003. Epub 2025 Dec 17. J Cyst Fibros. 2026. PMID: 41412872 Free PMC article.

86

A "story" of a woman with cystic fibrosis.

Highland KB, Flume PA. Highland KB, et al. Among authors: flume pa. Chest. 2002 May;121(5):1704-7. doi: 10.1378/chest.121.5.1704. Chest. 2002. PMID: 12006467

87

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Flume PA, et al. Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. doi: 10.1164/rccm.200705-664OC. Epub 2007 Aug 29. Am J Respir Crit Care Med. 2007. PMID: 17761616

88

Pulmonary complications in adult patients with cystic fibrosis.

Stenbit A, Flume PA. Stenbit A, et al. Among authors: flume pa. Am J Med Sci. 2008 Jan;335(1):55-9. doi: 10.1097/MAJ.0b013e31815d2611. Am J Med Sci. 2008. PMID: 18195585 Review.

89

Pulmonary exacerbations in cystic fibrosis.

Stenbit AE, Flume PA. Stenbit AE, et al. Among authors: flume pa. Curr Opin Pulm Med. 2011 Nov;17(6):442-7. doi: 10.1097/MCP.0b013e32834b8c04. Curr Opin Pulm Med. 2011. PMID: 21881509 Review.

90

State of progress in treating cystic fibrosis respiratory disease.

Flume PA, Van Devanter DR. Flume PA, et al. BMC Med. 2012 Aug 10;10:88. doi: 10.1186/1741-7015-10-88. BMC Med. 2012. PMID: 22883684 Free PMC article. Review.

91

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis.

Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, Fox HG, Gallagher CG, Geller DE, Haarman EG, Hebestreit HU, Kolbe J, Lapey A, Robinson P, Wu J, Zuckerman JB, Aitken ML; CF301 and CF302 Investigators. Bilton D, et al. Among authors: flume pa. J Cyst Fibros. 2013 Jul;12(4):367-76. doi: 10.1016/j.jcf.2012.11.002. Epub 2012 Dec 9. J Cyst Fibros. 2013. PMID: 23234802 Free article. Clinical Trial.

92

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. Boyle MP, et al. Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24. Lancet Respir Med. 2014. PMID: 24973281 Clinical Trial.

93

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Flume PA. Flume PA. J Cyst Fibros. 2016 Mar;15(2):139-40. doi: 10.1016/S1569-1993(16)00018-7. J Cyst Fibros. 2016. PMID: 27062882 Free article. No abstract available.

94

Adults with cystic fibrosis in Portugal: A first step towards improvement.

Raja TH, Flume PA. Raja TH, et al. Among authors: flume pa. Rev Port Pneumol (2006). 2016 May-Jun;22(3):139-40. doi: 10.1016/j.rppnen.2016.05.001. Rev Port Pneumol (2006). 2016. PMID: 27256624 Free article. No abstract available.

95

Bronchodilators in cystic fibrosis: a critical analysis.

Barry PJ, Flume PA. Barry PJ, et al. Among authors: flume pa. Expert Rev Respir Med. 2017 Jan;11(1):13-20. doi: 10.1080/17476348.2017.1246358. Epub 2016 Oct 27. Expert Rev Respir Med. 2017. PMID: 27718752 Review.

96

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group. Heltshe SL, et al. Among authors: flume pa. Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21. Contemp Clin Trials. 2018. PMID: 29170074 Free PMC article.

97

Unmet needs in cystic fibrosis: the next steps in improving outcomes.

West NE, Flume PA. West NE, et al. Among authors: flume pa. Expert Rev Respir Med. 2018 Jul;12(7):585-593. doi: 10.1080/17476348.2018.1483723. Epub 2018 Jun 19. Expert Rev Respir Med. 2018. PMID: 29855230 Free PMC article. Review.

98

Benefits of set length antibiotic treatment for pulmonary exacerbations.

Goss CH, Somayaji R, Flume PA. Goss CH, et al. Among authors: flume pa. Lancet Respir Med. 2018 Aug;6(8):575-577. doi: 10.1016/S2213-2600(18)30267-4. Epub 2018 Jun 27. Lancet Respir Med. 2018. PMID: 29960882 Free PMC article. No abstract available.

99

Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Flume PA, Chalmers JD, Olivier KN. Flume PA, et al. Lancet. 2018 Sep 8;392(10150):880-890. doi: 10.1016/S0140-6736(18)31767-7. Lancet. 2018. PMID: 30215383 Free PMC article. Review.

100

Pulmonary Complications of Cystic Fibrosis.

Garcia B, Flume PA. Garcia B, et al. Among authors: flume pa. Semin Respir Crit Care Med. 2019 Dec;40(6):804-809. doi: 10.1055/s-0039-1697639. Epub 2019 Oct 28. Semin Respir Crit Care Med. 2019. PMID: 31659729 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

222 results

Search Page

Filters